nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2020-1-22-26nnp-1256Research ArticleORIGINAL INVESTIGATIONSОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ И МЕТОДИКИAssociation of BAFF gene polymorphisms with multiple sclerosis progressionАссоциация полиморфизмов гена BAFF с прогрессированием рассеянного склерозаСмагинаИ. В.SmaginaI. V.

656038, Барнаул, просп. Ленина, 40

656024, Барнаул, ул. Ляпидевского, 1

40, Lenin Prosp., Barnaul 656038

1, Lyapidevsky St., Barnaul 656024

siv7000@yandex.ruЕльчаниноваС. А.ElchaninovaS. A.

656038, Барнаул, просп. Ленина, 40

40, Lenin Prosp., Barnaul 656038

ПалащенкоА. С.PalashchenkoA. S.

656038, Барнаул, просп. Ленина, 40

656024, Барнаул, ул. Ляпидевского, 1 

40, Lenin Prosp., Barnaul 656038

1, Lyapidevsky St., Barnaul 656024 

ФГБОУ ВО «Алтайский государственный медицинский университет» Минздрава России; КГБУЗ «Краевая клиническая больница»РоссияAltai State Medical University, Ministry of Health of Russia; Territorial Clinical HospitalRussian FederationФГБОУ ВО «Алтайский государственный медицинский университет» Минздрава РоссииРоссияAltai State Medical University, Ministry of Health of RussiaRussian Federation2020190220201212226Copyright © Smagina I.V., Elchaninova S.A., Palashchenko A.S., 20202020Смагина И.В., Ельчанинова С.А., Палащенко А.С.Smagina I.V., Elchaninova S.A., Palashchenko A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/1256рассеянный склерозфактор активации B-клетокTNFSF13Bполиморфизмыmultiple sclerosisB-cell activation factorTNFSF13BpolymorphismsReferencesГуceв EИ, Зaвaлишин ИA, Бoйкo AН. Pacceянный cклepoз. Клиничecкoe pукoвoдcтвo. Москва: Peaл Тaйм; 2011. 528 с.Gusev EI, Zavalishin IA, Boiko AN. Rasseyannyi skleroz. Klinicheskoe rukovodstvo [Multiple sclerosis. Clinical guidance]. Moscow: Peal Taim; 2011. 528 p.Bеdri SK, Fink K, Mаnоuсhеhriniа А, et al. Multiрlе sсlеrоsis trеаtmеnt еffесts оn рlаsmа сytоkinе rесерtоr lеvеls. Clin Immunol. 2018 Feb;187:15-25. doi: 10.1016/j.clim.2017.08.023. Epub 2017 Sep 21.Bеdri SK, Fink K, Mаnоuсhеhriniа А, et al. Multiрlе sсlеrоsis trеаtmеnt еffесts оn рlаsmа сytоkinе rесерtоr lеvеls. Clin Immunol. 2018 Feb;187:15-25. doi: 10.1016/j.clim.2017.08.023. Epub 2017 Sep 21.International Multiple Sclerosis Genetics Consortium; Beecham AH, Patsopoulos NA, Xifara DK, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013 Nov; 45(11):1353-60. doi: 10.1038/ng.2770. Epub 2013 Sep 29.International Multiple Sclerosis Genetics Consortium; Beecham AH, Patsopoulos NA, Xifara DK, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013 Nov; 45(11):1353-60. doi: 10.1038/ng.2770. Epub 2013 Sep 29.Palle P, Monaghan KL, Milne SM, Wan Edwin CK. Сytоkinе signаling in multiрlе sсlеrоsis аnd its thеrареutiс аррliсаtiоns. Med Sci (Basel). 2017 Oct 13;5(4). pii: E0023. doi: 10.3390/medsci5040023.Palle P, Monaghan KL, Milne SM, Wan Edwin CK. Сytоkinе signаling in multiрlе sсlеrоsis аnd its thеrареutiс аррliсаtiоns. Med Sci (Basel). 2017 Oct 13;5(4). pii: E0023. doi: 10.3390/medsci5040023.Rickert RC, Jellusova J, Miletic AV. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev. 2011 Nov;244(1):115-33. doi: 10.1111/j.1600-065X.2011.01067.x.Rickert RC, Jellusova J, Miletic AV. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev. 2011 Nov;244(1):115-33. doi: 10.1111/j.1600-065X.2011.01067.x.Rahmanzadeh R, Weber MS, Brü ck W, et al. B cells in multiple sclerosistherapy A comprehensive review. Acta Neurol Scand. 2018 Jun; 137(6):544-556. doi: 10.1111/ane.12915. Epub 2018 Mar 7.Rahmanzadeh R, Weber MS, Brü ck W, et al. B cells in multiple sclerosistherapy A comprehensive review. Acta Neurol Scand. 2018 Jun; 137(6):544-556. doi: 10.1111/ane.12915. Epub 2018 Mar 7.Marin-Rosales M, Cruz A, Salazar-Camarena DC, et al. High BAFF expression associated with active disease in systemic lupus erythematosus and relationship with rs9514828C>T polymorphism in TNFSF13B gene. Clin Exp Med. 2019 May;19(2):183-190. doi: 10.1007/s10238-019-00549-8. Epub 2019 Feb 11.Marin-Rosales M, Cruz A, Salazar-Camarena DC, et al. High BAFF expression associated with active disease in systemic lupus erythematosus and relationship with rs9514828C>T polymorphism in TNFSF13B gene. Clin Exp Med. 2019 May;19(2):183-190. doi: 10.1007/s10238-019-00549-8. Epub 2019 Feb 11.Nezos A, Papageorgiou A, Fragoulis G, et al. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. J Autoimmun. 2014 Jun;51:89-98. doi: 10.1016/j.jaut.2013.04.005. Epub 2013 Jul 9.Nezos A, Papageorgiou A, Fragoulis G, et al. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. J Autoimmun. 2014 Jun;51:89-98. doi: 10.1016/j.jaut.2013.04.005. Epub 2013 Jul 9.Steri M, Orru V, Idda ML, et al. Overexpression of the cytokine BAFF and autoimmunity risk. N Engl J Med. 2017 Apr 27; 376(17):1615-1626. doi: 10.1056/NEJMoa1610528.Steri M, Orru V, Idda ML, et al. Overexpression of the cytokine BAFF and autoimmunity risk. N Engl J Med. 2017 Apr 27; 376(17):1615-1626. doi: 10.1056/NEJMoa1610528.Gonza’lez-Serna D, Carmona EG, Ortego-Centeno N, et al. A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility. PLoS One. 2018 Dec 26;13(12):e0209343. doi: 10.1371/journal.pone.0209343. eCollection 2018.Gonza’lez-Serna D, Carmona EG, Ortego-Centeno N, et al. A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility. PLoS One. 2018 Dec 26;13(12):e0209343. doi: 10.1371/journal.pone.0209343. eCollection 2018.Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol. 2011 Feb;69(2):292-302. doi: 10.1002/ana.22366.Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol. 2011 Feb;69(2):292-302. doi: 10.1002/ana.22366.Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11): 1444-52.Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11): 1444-52.Малкова НА, Иерусалимский АП. Рассеянный склероз. Новосибирск; 2006. 198 с.Malkova NA, Ierusalimskii AP. Rasseyannyi skleroz [Multiрlе sсlеrоsis]. Novosibirsk; 2006. 198 p.Смагина ИВ, Ельчанинова СА, Золовкина АГ, Гридина АО. Факторы, Ассоциированные с высокой скоростью прогрессирования рассеянного склероза. Журнал неврологии и психиатрии им. C.C. Корсакова. 2011;111(2-2):25-9.Smagina IV, El'chaninova SA, Zolovkina AG, Gridina AO. Factors associated with high rate of multiple sclerosis progression. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2011;111(2-2):25-9. (In Russ.).Sonar S, Lal G. Role of tumor necrosis factor superfamily in neuroinflammation and autoimmunity. Front Immunol. 2015 Jul 20; 6:364. doi: 10.3389/fimmu.2015.00364. eCollection 2015.Sonar S, Lal G. Role of tumor necrosis factor superfamily in neuroinflammation and autoimmunity. Front Immunol. 2015 Jul 20; 6:364. doi: 10.3389/fimmu.2015.00364. eCollection 2015.Kannel K, Alnek K, Vahter L, et al. Changes in Blood B Cell Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome. PLoS One. 2015 Nov 23; 10(11):e0143393. doi: 10.1371/journal.pone.0143393. eCollection 2015.Kannel K, Alnek K, Vahter L, et al. Changes in Blood B Cell Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome. PLoS One. 2015 Nov 23; 10(11):e0143393. doi: 10.1371/journal.pone.0143393. eCollection 2015.Baker D, Marta M, Pryce G, et al. Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. E BioMedicine. 2017 Feb;16:41-50. doi: 10.1016/j.ebiom.2017.01.042. Epub 2017 Jan 31.Baker D, Marta M, Pryce G, et al. Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. E BioMedicine. 2017 Feb;16:41-50. doi: 10.1016/j.ebiom.2017.01.042. Epub 2017 Jan 31.Ragheb S, Li Y, Simon K, et al. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult Scler. 2011 Jul;17(7):819-29. doi: 10.1177/1352458511398887. Epub 2011 Mar 3.Ragheb S, Li Y, Simon K, et al. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult Scler. 2011 Jul;17(7):819-29. doi: 10.1177/1352458511398887. Epub 2011 Mar 3.Krumbholz M, Theil D, Derfuss T, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med. 2005 Jan 17;201(2):195-200. Epub 2005 Jan 10.Krumbholz M, Theil D, Derfuss T, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med. 2005 Jan 17;201(2):195-200. Epub 2005 Jan 10.

The authors declare that there are no conflicts of interest present.